An observational study in Primary Mitochondrial Myopathies, sponsored by Cristina Domínguez González. Recruiting at 1 site in Spain. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2025-09-16.
Sponsored by Cristina Domínguez González · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a longitudinal study in a cohort of patients with a genetic diagnosis of Primary Mitochondrial Myopathy to describe the natural history of the disease and identify clinical, biochemical, molecular, and radiological variables that allow evaluation of the severity and progression of the disease and may be useful in future clinical trials.
Mitochondrial Diseases (MD) are among the most frequent inherited metabolic diseases. Despite their high impact on patients, there are still no authorized drugs capable of modifying their clinical course. MD are clinically and genetically heterogeneous disorders, with muscular symptoms being one of their main manifestations. When muscular symptoms predominate, the disorder is classified as a Primary Mitochondrial Myopathy. In recent years, there have been significant advances in developing potential new treatments in this field. However, the absence of natural history studies makes the design and interpretation of clinical trials difficult and leads to long delays or even failures in the development of new treatments. The investigators propose to characterize in-depth a cohort of patients with Primary Mitochondrial Disorders due to mutations in the mitochondrial DNA (mtDNA) or in genes located in the nuclear genome (nDNA), from a clinical perspective but also a radiological, biochemical, and molecular point of view, and carry out a longitudinal follow-up of these parameters to identify those that are better correlated with severity and that allow measuring changes in the patient's clinical situation. With this objective, the investigators will analyze clinical variables (evaluation of motor function through manual force exploration, functional scales, and timed test, quality of life scales, serum biomarkers (growth differentiation factor 15 (GDF15) and fibroblast growth factor 21 (FGF21)), levels of heteroplasmy for cases harboring mtDNA mutations and mtDNA copy-number, and muscle magnetic resonance image of the lower extremities with quantification of fat replacement. All parameters will be evaluated at the beginning of the study and then annually during two years of follow-up.
46 studies on the registry are indexed under Mitochondrial Myopathies; 14 are open to participants now.
This study's planned enrollment of 150 is above the median of 42 across 15 observational studies indexed under Mitochondrial Myopathies.
Browse Mitochondrial Myopathies studies →Cristina Domínguez González is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with Primary Mitochondrial Myopathy with a genetic diagnosis
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Mitochondrial myopathy, confirmed genetically
Motor Function (endurance)
6 minute walking test (6MWT)
Time frame: 36 months
Motor Function (functional scale)
North Star Ambulatory Assessment (NSAA)
Time frame: 36 months
Biomarkers
Analysis of levels of GDF15 y FGF21 annually
Time frame: 36 months
Levels of heteroplasmy
Analysis of levels of heteroplasmy annually
Time frame: 36 months
Muscle magenitc resonance image (MRI)
Quantification of the fat fraction in muscle MRI, annually
Time frame: 36 months
Plan to share: No
Started Jan 2023 (actual). Primary completion is estimated for Jun 2026, 41 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cristina Domínguez González